Rocket


News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

InflaRx N.V. (IFRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "REPORT OF FOREIGN PRIVATE ISSUER",
"InflaRx N.V. Unaudited Condensed Consolidated Financial Statements as of and for the Three and Six Months Ended June 30, 2023",
"InflaRx N.V. Management’s Discussion and Analysis of Financial Condition and Results of Operations",
"INFLARX N.V. PRESS RELEASE DATED AUGUST 10, 2023"
07/12/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/12/2023 EFFECT Form EFFECT - Notice of Effectiveness:
06/30/2023 F-3 Form F-3 - Registration statement by foreign private issuers:
05/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"InflaRx N.V. Unaudited Condensed Consolidated Financial Statements as of and for the Three Months Ended March 31, 2023",
"InflaRx N.V. Management’s Discussion and Analysis of Financial Condition and Results of Operations",
"InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update"
04/27/2023 6-K Quarterly results
04/24/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
04/17/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
04/13/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Underwriting Agreement, between InflaRx N.V. and Raymond James & Associates, Inc., as representative of the underwriters named in Schedule 1 therein",
"Opinion of Nauta Dutilh N.V"
04/05/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Convening Notice, including Agenda and Explanatory Notes",
"Voting Proxy"
03/22/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/22/2023 6-K Quarterly results
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/05/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients"
12/21/2022 6-K Quarterly results
11/09/2022 6-K Quarterly results
11/09/2022 6-K Quarterly results
09/29/2022 6-K Quarterly results
09/08/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Jena, Germany, September 08, 2022 – InflaRx N.V. , a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that the previously reported results from its Phase III trial of vilobelimab to treat critically ill, invasively mechanically ventilated COVID-19 patients have been published in the peer-reviewed journal, The Lancet Respiratory Medicine"
08/05/2022 6-K Quarterly results
07/26/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Jena, Germany, July 26, 2022"
07/06/2022 6-K Quarterly results
06/29/2022 6-K Quarterly results
05/12/2022 6-K Quarterly results
04/28/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
04/07/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Convening Notice, including Agenda and Explanatory Notes",
"Voting Proxy"
03/31/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients"
03/24/2022 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/24/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"InflaRx Reports Full Year 2021 Financial and Operating Results"
03/17/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Jena, Germany, March 17, 2022"
03/08/2022 6-K Quarterly results
02/28/2022 6-K Quarterly results
02/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Jena, Germany, February 16, 2022 – InflaRx N.V. , a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the start of the second dosing cohort of the vilobelimab and PD-1 checkpoint inhibitor, pembrolizumab, combination arm of the Phase II clinical trial in cutaneous squamous cell carcinoma . The open label, non-comparative, two-stage, Phase II trial is ongoing at sites in Europe, the U.S. and elsewhere. The study is investigating two independent arms: vilobelimab alone and vilobelimab in combination with pembrolizumab . The main objectives of the trial are to assess the safety and antitumor activity of vilobelimab monotherapy and to determine the maximum tolerated or recommended dose, safety and antitumor ac..."
02/14/2022 SC 13G/A GREAT POINT PARTNERS LLC reports a 0% stake in InflaRx N.V.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy